Despite intensive research since the pandemic began, much remains unknown about COVID-19, particularly why it can be so severe in some cases and relatively mild in others.
Spexis granted definitive moratorium status until 25 November 2024, subject to monthly progress report obligations, and which can be potentially extended at the request of the administrators. – Biotech Investments
Spexis AG / Key word(s): Miscellaneous 29-Jul-2024 / 07:15 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely
July 30, 2024